Guardant Health announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval PMA application for the company’s Shield(TM) blood test for colorectal cancer CRC screening on Thursday, May 23. “We look forward to discussing with the FDA Advisory Committee and its panel of experts the clinical data from our ECLIPSE study and the potential for the Shield blood test to overcome the barriers of current screening methods and offer a new, more convenient screening option that will detect colorectal cancer in the early stages, when it is most treatable,” said AmirAli Talasaz, co-CEO of Guardant Health.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health to present data on epigenomics at 2024 AACR meeting
- Canaccord positive on Exact, Guardant after Freenome data
- Exact Sciences, Guardant rally after Freenome colorectal cancer test results
- Guardant Health Revises Co-CEOs’ Compensation and Incentives
- Guardant Health’s ECLIPSE study data demonstrates efficacy of Shield blood test